R1 RCM’s latest acquisition is expected to add about $240 million to the company’s 2022 revenue, executives said Monday.
The revenue-cycle management company completed its acquisition of Cloudmed, announced in January, last week. Cloudmed is a technology company that uses artificial intelligence and automation to analyze medical records, payment data and medical insurance models to help healthcare providers manage claims and payments.
R1 has sought to differentiate itself from competitors by developing technology tools with robotic process automation, machine learning and natural language processing.
“Cloudmed is a very significant asset for us,” said R1 CEO Joe Flanagan Monday during a call with investment analysts.
Here are five things to know about the deal and R1’s plans for Cloudmed.
1. R1 purchased the privately held Cloudmed for $4.1 billion, including $857 million of net debt. R1 issued 135.9 million shares to Cloudmed shareholders, who now own about 30% of the combined company.
2. The company is already bringing R1 tools to Cloudmed’s customers. Flanagan previously said the combined company’s customer base would accelerate R1’s machine-learning efforts.
3. R1 raised its 2022 revenue guidance to between $1.85 billion and $1.870 billion, from $1.66 billion to $1.7 billion previously. Last year, R1 reported $1.5 billion in revenue.
4. The company’s 2022 guidance for adjusted earnings before interest, taxes, depreciation and amortization is between $470 million and $480 million, up from an earlier projection of $385 million to $405 million and higher than the company’s 2021 adjusted EBITDA of $343.6 million. The new guidance factors in an additional $105 million from Cloudmed.
5. Lee Rivas, formerly Cloudmed’s CEO, joined R1 as its president. As part of the acquisition, R1 added three board seats for directors nominated by Cloudmed investor New Mountain Capital.